Patrick Fourteau insider trades: Insys Therapeutics (INSY) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Patrick reports to the SEC
Open-market buys and sales
25 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 11, 2016 | INSY | ↓ Sell | 15,000 | $18.46 | $277K | Direct | Aug 12, 2016 (1d) |
| Mar 4, 2016 | INSY | ↓ Sell | 15,000 | $18.22 | $273K | Direct | Mar 4, 2016 (0d) |
| Nov 12, 2015 | INSY | ↓ Sell | 30,000 | $26.48 | $794K | Direct | Nov 13, 2015 (1d) |
| May 27, 2015 | INSY | ↓ Sell | 6,095 | $60.03 | $366K | Direct | May 27, 2015 (0d) |
| May 20, 2015 | INSY | ↓ Sell | 9,064 | $60.00 | $544K | Direct | May 20, 2015 (0d) |
| Mar 11, 2015 | INSY | ↓ Sell | 10,000 | $59.94 | $599K | Direct | Mar 12, 2015 (1d) |
| Nov 19, 2014 | INSY | ↓ Sell | 25,000 | $39.11 | $978K | Direct | Nov 20, 2014 (1d) |
| May 15, 2014 | INSY | ↑ Buy | 7,500 | $22.77 | $171K | Direct | May 15, 2014 (0d) |
| Aug 14, 2013 | INSY | ↑ Buy | 5,000 | $23.77 | $119K | Direct | Aug 15, 2013 (1d) |
| May 14, 2013 | INSY | ↑ Buy | 5,000 | $10.90 | $55K | Direct | May 14, 2013 (0d) |
| May 13, 2013 | INSY | ↑ Buy | 4,800 | $10.90 | $52K | Direct | May 13, 2013 (0d) |
| May 8, 2013 | INSY | ↑ Buy | 200 | $10.40 | $2K | Direct | May 13, 2013 (5d) |
| May 7, 2013 | INSY | ↑ Buy | 50,000 | $8.36 | $418K | Direct | May 8, 2013 (1d) |
| Aug 15, 2008 | SCRX | ↓ Sell10b5-1 | 100,000 | $21.37 | $2.1M | Direct | Aug 18, 2008 (3d) |
| May 15, 2008 | SCRX | ↓ Sell10b5-1 | 100,000 | $21.08 | $2.1M | Direct | May 19, 2008 (4d) |
| Feb 15, 2008 | SCRX | ↓ Sell10b5-1 | 52,500 | $22.45 | $1.2M | Direct | Feb 20, 2008 (5d) |
| Jan 24, 2008 | SCRX | ↓ Sell10b5-1 | 24,008 | $22.88 | $549K | Direct | Jan 25, 2008 (1d) |
| Dec 7, 2007 | SCRX | ↓ Sell10b5-1 | 28,750 | $22.75 | $654K | Direct | Dec 10, 2007 (3d) |
| Oct 31, 2007 | SCRX | ↓ Sell10b5-1 | 50,000 | $25.25 | $1.3M | Direct | Nov 2, 2007 (2d) |
| Sep 10, 2007 | SCRX | ↓ Sell10b5-1 | 100,000 | $24.90 | $2.5M | Direct | Sep 12, 2007 (2d) |
| May 16, 2007 | SCRX | ↓ Sell10b5-1 | 52,500 | $24.11 | $1.3M | Direct | May 17, 2007 (1d) |
| Jan 24, 2007 | SCRX | ↓ Sell10b5-1 | 17,500 | $23.88 | $418K | Direct | Jan 26, 2007 (2d) |
| Nov 1, 2006 | SCRX | ↓ Sell10b5-1 | 50,000 | $21.70 | $1.1M | Direct | Nov 2, 2006 (1d) |
| Aug 2, 2006 | SCRX | ↓ Sell10b5-1 | 49,924 | $20.11 | $1.0M | Shares owned by spouse | Aug 2, 2006 (0d) |
| May 16, 2006 | FHRX | ↓ Sell10b5-1 | 105,000 | $23.50 | $2.5M | Direct | May 18, 2006 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Patrick Fourteau's insider trades
Patrick Fourteau is a director at Insys Therapeutics (INSY). Since May 16, 2006, Patrick has reported 6 open-market purchases worth $817K and 19 sales worth $20.5M on SEC Form 4. There have been no open-market trades in the last 12 months.
12 sales (81% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (13 filings), option exercises (8 filings), shares returned to the company (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every INSY insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.